Wednesday, October 3, 2018

Reported by Jules Levin - Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs

Reported by Jules Levin
Executive Director, NATAP 

7th International Symposium on Hepatitis Care in Substance Users
Cascais, Portugal
19 - 21 September 2018

*Full-Text article available for download @ NATAP

Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
Introduction. Young adults who inject drugs and live in rural communities are at high risk for hepatitis C virus (HCV) infection. Recent changes in HCV treatment must be communicated within these communities to improve access to care and reduce HCV transmission.

Methods. Field workers in the ¡VÁLE! Hepatitis Treatment and Integrated Prevention Services study identified frequently asked questions (FAQs) posed by young-adult participants at high risk for HCV during screening and educational sessions. From 2016 to 2018, 183 young adults (44.3% women; 85.8% Latino/a) younger than 30 years who inject drugs and reside in Rio Arriba or Doña Ana counties in New Mexico were enrolled. The research team compiled deidentified questions during field enrollments.

Results. FAQs were reviewed and categorized into four major domains, including risk/prevention, screening, treatment, and reinfection. FAQs were addressed by a team of medical and public health professionals, using the most current research and recommendations.

Conclusions. These FAQs address important gaps in HCV knowledge among young adults who are at high risk for infection. The FAQs also highlight the importance of risk reduction counseling provided by frontline public health providers as well as access to safe and effective HCV treatments for young adults who inject drugs.

Continue to complete article:

Recommended Reading
7th International Symposium on Hepatitis Care in Substance Users (INSHU)

INSHU: High Cure Rates in a Real world Cohort of HCV Infected Patients on Opioid Substitution Therapy (OST) Despite Alcohol and Cannabis Consumption Data from The German Hepatitis C-Registry (DHC-R) - (10/01/18)

INSHU: Treatment as prevention approach results in early and marked prevalence reduction of hepatitis C viremia among people who recently injected drugs. Results from Iceland: Treatment as Prevention (TraPHepC) - (10/01/18)

INSHU: Drug use and reinfection during and following Hepatitis C Virus treatment with Elbasvir/Grazoprevir among patients receiving Opiate Agonist Therapy: C-EDGE Co-STAR study - (10/01/18)

INSHU: New Questions About HCV From a New Generation - (10/01/18)

INSHU: C Change: Philadelphia's Plan to Eliminate Hepatitis C Among People Who Use Injection Drugs - (10/01/18)

INSHU: Building Bridges to Eliminate HCV in PWID Building Bridges to Reach People Who Inject Drugs with the Goal to Eliminate HCV - (10/01/18)

INSHU: A Screening Program for Hepatitis C among Baby Boomers in the Northeast United States reveals an Alarmingly High Prevalence of HCV among People who Inject Drugs - (10/01/18)

More Hep C Articles @ NATAP...

No comments:

Post a Comment